Prognostic importance of cognitive impairment in chronic heart failure patients: does specialist management make a difference?

Eur J Heart Fail. 2006 Aug;8(5):494-501. doi: 10.1016/j.ejheart.2005.11.013. Epub 2006 Feb 28.


Background: Cognitive impairment is common among chronic heart failure (CHF) patients.

Aims: To determine the prognostic significance of cognitive impairment in patients participating in a randomized study of a CHF management program (CHF-MP).

Methods: CHF patients were randomized to a CHF-MP (n=100) or usual care (n=100). Baseline cognition was assessed using the Mini Mental Status Examination (MMSE). Five-year all-cause mortality, and combined death-or-readmission, were compared on the basis of the presence (MMSE 19-26) or absence (MMSE >26) of cognitive impairment.

Results: 27 patients (13.5%) had cognitive impairment and, on an adjusted basis, were more likely to die (96.3% versus 68.2%. RR 2.19, 95% CI 1.41 to 3.39: P<0.001) and/or experience an unplanned hospitalization (100% versus 94%. RR 1.44, 95% CI 1.06 to 1.95: P=0.019). Cognitively impaired patients had a similar (non-significant) adjusted risk of death-or-readmission in both the CHF-MP (RR 1.40, 95% CI 0.63 to 3.11: P=0.403) and in usual care (RR 1.38, 95% CI 0.75 to 2.53: P=0.305). In the usual care cohort, cognitive impairment was associated with a greater (non-significant), adjusted risk of death (RR 1.61, 95% CI 1.10 to 4.92: P=0.122). In the CHF-MP, adjusted risk of death was significantly higher for cognitively impaired patients (RR 2.33, 95% CI 1.10 to 4.92: P=0.027).

Conclusion: These data suggest that "mild" cognitive impairment is of prognostic importance in CHF: even when a CHF-MP has been applied.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Cognition Disorders / epidemiology*
  • Comorbidity
  • Female
  • Heart Failure / epidemiology*
  • Heart Failure / mortality*
  • Humans
  • Male
  • Prognosis
  • Proportional Hazards Models
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Survival Analysis